Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 2Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 24Gastrointestinal 11Head & Neck 8Lymphoid 3Breast 3Sarcoma 2Gynecologic 2Dermatologic 2CNS 2

Conditions

Melanoma 2

Interventions

Nivolumab 27pembrolizumab 22Ipilimumab 17Temozolomide 13toripalimab 12Biopsy 10Cyclophosphamide 9Imiquimod 8Dacarbazine 7Blood Specimen Collection 7camrelizumab 6Chemotherapy, Adjuvant 6trametinib 5fludarabine 5dabrafenib 5atezolizumab 5aldesleukin 5Gene Expression Profiling 5Cisplatin 5Aminolevulinic Acid 5fludarabine phosphate 4durvalumab 4binimetinib 4apatinib 4Tomography, Optical Coherence 4Sorafenib 4Photochemotherapy 4Interleukin-2 4Injections 4Carboplatin 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × endostar protein × Dermatologic × Clear all
NCT05907512 2023-06-22

Endostar Plus Toripalimab as Adjuvant Therapy for Resectable Stage III-Oligometastatic Stage IV Cutaneous Melanoma

Fudan University

Phase 2 Unknown
43 enrolled
Dermatologic

Melanoma

NCT03095079 2017-03-29

Rh-endostatin in Combination With Dacarbazine and Cisplatin as the First Line Therapy for Metastatic Melanoma

Peking University Cancer Hospital & Institute

Phase 2 Unknown
70 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡